The Rise, Fall And Steep Climb Of Aquinox Pharma… – Nasdaq
The Rise, Fall And Steep Climb Of Aquinox Pharma…NasdaqOn May 4, 2015, the company announced that it has reached its target enrollment of 50 patients in a phase II trial of AQX-1125 for the treatment of atopic dermatitis, dubbed KINSHIP. The stock closed at $6.72 that day. Then followed a couple of bad …Aquinoxs Shares Shoot Up, Bladder Pain Drug in FocusZacks.comall 4 news articles »
[monetize id=”1″]
[monetize id=”2″]
Eczema Action Plan (Atopic Dermatitis)
Xeljanz may reduce atopic dermatitis symptoms – Healio
Xeljanz may reduce atopic dermatitis symptomsHealioBrett A. King, MD, PhD, assistant professor of dermatology, Yale School of Medicine, and colleagues studied six adults (aged 18 to 55 years) with moderate-to-severe atopic dermatitis who had failed standard treatment were treated with Xeljanz …and more »
